-
RG108 DNA Methyltransferase Inhibitor: Lab Guide
2026-08-26
RG108 is a practical DNA methyltransferase inhibitor for testing methylation-dependent gene silencing without relying on covalent enzyme trapping. This guide translates product specifications and an in vivo reprogramming study into cell-culture workflows, assay controls, and troubleshooting decisions for epigenetics and cancer research.
-
Melittin B6628 for Reliable Cell Assays
2026-08-25
Learn how Melittin, a bioactive peptide supplied as SKU B6628, can support more interpretable viability, signaling, and cancer-biology experiments. This scenario-based guide covers formulation, controls, storage, protocol design, and responsible interpretation alongside evidence from glioblastoma research.
-
SLU-PP-332: ERR Agonism and Kidney-Relevant Metabolism
2026-08-25
This 2024 nephrology News and Views article interprets SLU-PP-332 as a preclinical exercise-mimetic strategy that activates estrogen-related receptors, increases energy expenditure, and supports oxidative skeletal-muscle metabolism. Its most important contribution is the proposed link between improved systemic metabolism and indirect kidney protection, while also emphasizing that direct renal efficacy and clinical safety remain unproven.
-
From Adipose Mechanisms to Safer Gel Imaging
2026-08-24
A translational perspective linking FMO3–TMAO adipose biology with rigorous nucleic acid quality control, safer imaging, and more reliable molecular workflows using Safe DNA Gel Stain.
-
PINK1/Park2 Mitophagy in Fatty Liver Disease
2026-08-24
The reference study links Park2-mediated mitophagy to reduced lipid accumulation, inflammation, and mitochondrial injury in an oleic acid-induced NAFLD model. Its gain- and loss-of-function design provides mechanistic evidence that restoring mitochondrial quality control may be relevant to NAFLD research, while remaining limited by its primarily cellular experimental system.
-
Safe DNA Gel Stain: Signal Without the Trade-Off
2026-08-23
Safe DNA Gel Stain enables sensitive DNA and RNA gel stain workflows with blue-light or UV excitation. This article explains how to choose, validate, and interpret safer nucleic acid visualization methods using an assay-design framework informed by reporter-gene research.
-
Hoechst 33258 for TNT Tumor Cell Imaging
2026-08-22
Hoechst 33258 turns nuclear labeling into a practical control layer for studying KRas-associated tumor heterogeneity, tunneling nanotubes, and cell-state changes. This workflow explains how to combine a bis-benzimide DNA stain with confocal imaging, cell counting, and cell-cycle analysis without mistaking nuclear fluorescence for a direct readout of KRas transfer or membrane mechanics.
-
Mitoxantrone HCl: Topoisomerase II Mechanisms
2026-08-22
Mitoxantrone HCl is a DNA topoisomerase II inhibitor that links DNA damage biology with apoptosis, immune-cell modulation, and ERα receptor regulation. The reference study identifies an ERα DBD–LBD interface mechanism that can suppress wild-type and endocrine-resistant ERα signaling independently of DNA damage.
-
3X (DYKDDDDK) Peptide for Reliable Assays
2026-08-21
Learn how 3X (DYKDDDDK) Peptide, SKU A6001, can improve FLAG-fusion detection and protein workflow control without being mistaken for a cell-viability reagent. This scenario-based guide covers assay compatibility, storage, metal-sensitive conditions, interpretation, and practical vendor selection.
-
ATS-9R for Targeted Gene Silencing in Adipocytes
2026-08-20
ATS-9R combines Prohibitin recognition with a nona-arginine nucleic-acid carrier to focus gene delivery on white adipose tissue. This article presents practical complexation, cell and animal workflows, assay controls, and troubleshooting strategies for obesity-associated inflammation research and metabolic disease models.
-
Decitabine Workflow for Epigenetic Research
2026-08-20
Build dose-resolved Decitabine assays that separate DNA hypomethylation, immune reprogramming, and cytotoxicity. This workflow translates evidence from T-cell homeostasis research into practical designs for hematopoietic malignancy research and solid tumor epigenetic studies.
-
Mebendazole, TUBA1A, and PANoptosis in AML
2026-08-19
The reference study identifies mebendazole as a preclinical anti-AML agent and links its activity to TUBA1A disruption, G2/M cell-cycle arrest, and ZBP1-mediated PANoptosis. Its integrated screening, mechanistic, and xenograft workflow offers a useful framework for drug repositioning screening while highlighting the evidence still needed before clinical translation.
-
Hoechst 33258 for DNA-Resolved Tumor Mechanics
2026-08-19
Hoechst 33258 is a bis-benzimide DNA stain that can anchor live-cell imaging and nuclear segmentation in studies of tumor-cell mechanics. This article explains how to use its DNA readout alongside confocal microscopy and optical-tweezers experiments without confusing nuclear labeling with direct evidence of KRas transport.
-
Cisplatin Beyond Cytotoxicity: A Translational Playbook
2026-08-18
Cisplatin and CDDP remain essential translational benchmarks because they connect DNA crosslinking, p53 and caspase-dependent apoptosis, oxidative stress, and treatment resistance in one experimentally tractable system. This thought-leadership guide shows how to use Cisplatin as a mechanistic reference point while interpreting pathway-focused findings such as those reported for cepharanthine in nasopharyngeal carcinoma.
-
Malate Workflows for Tumor Immunometabolism
2026-08-18
Use malate as a controlled metabolic probe to connect mitochondrial redox, TCA-cycle flux, and macrophage function in cholangiocarcinoma models. This workflow translates a recent PDHA1 succinylation study into practical cell, mitochondrial, and troubleshooting strategies without assuming that malate directly reproduces the paper’s alpha-ketoglutarate mechanism.